Analysis of the Severity and Prognosis of Pulmonary Hypertension Associated With Bronchiectasis.
Analysis of the Severity and Prognosis of Pulmonary Hypertension Associated With Bronchiectasis.
Through analysis of demographic factors (gender, age, smoking history and body mass index),
 clinical indicators (signs and symptoms), sputum culture results (pseudomonas aeruginosa),
 brain natriuretic peptide and imaging (scope and type of bronchiectasis), pulmonary function
 index, inflammatory cytokines and inflammasome of patients, some factors will be found which
 maybe be related to severity and prognosis of pulmonary hypertension associated with
 bronchiectasis.
The patients with bronchiectasis during the past five years were retrospectively analyzed.
 Demographic factors (gender, age, smoking history and body mass index), clinical indicators
 (signs and symptoms), sputum culture results (pseudomonas aeruginosa), brain natriuretic
 peptide and imaging (scope and type of bronchiectasis), pulmonary function index, pulmonary
 artery systolic pressure through doppler ultrasound, prognosis, the number of exacerbation in
 the past year and hospitalization days will be analyzed. Different groups: bronchiectasis
 with pulmonary hypertension and bronchiectasis without pulmonary hypertension according to
 the results of doppler ultrasound; mild (40mmHg ≤ SPAP < 60mmHg), moderate (60mmHg ≤ SPAP <
 80mmHg), and severe (80mmHg ≤ SPAP) group according to SPAP level; survival and death groups
 according to the results of follow-up. Above indexes between the different groups will be
 analyzed to explore which factors can be independent factors combined with bronchiectasis
 pulmonary hypertension, the degree of pulmonary artery systolic pressure, and the prognosis
 of patients.

 60 bronchiectasis patients will be enrolled in a prospective study, and divided into two
 groups (bronchiectasis with pulmonary hypertension and bronchiectasis without pulmonary
 hypertension). Interleukin 1 beta, IL - 18, endothelin 1 in peripheral blood and
 bronchoalveolar lavage from patients will be examined through enzyme linked immunosorbent
 assays (ELISA). NLRP3 inflammasome, ASC, caspase 1 mRNA expression from peripheral blood
 mononuclear cells and mucous membrane of the bronchial lung tissues will be examined through
 RT-PCR method.

 The correlation indexes between different groups were compared and analyzed to explore which
 factors were associated with bronchiectasis and pulmonary hypertension.
Inclusion Criteria:

 1. Diffuse distribution of bronchiectasis in chest CT.

 2. The moderate and severe cases (Bronchiectasis Severity Score (BSI) of the patients
 with bronchiectasis is greater than 5 points).

 3. The average pulmonary hypertension through right cardiac catheterization is great than
 20 mmHg, the pulmonary capillarity pressure is less than 15mmHg.

 Exclusion Criteria:

 1. Patients with allergic bronchopulmonary aspergillosis (ABPA).

 2. Patients with bronchiectasis combined with pulmonary tuberculosis and non-tuberculous
 mycobacterium tuberculosis.

 3. Patients with bronchiectasis due to genetic factors.

 4. Bronchiectasis patients with connective tissue diseases.

 5. Patients with bronchiectasis with interstitial lung disease.

 6. Combined with pulmonary embolism, pneumothorax, mediastinal emphysema and lung tumor.

 7. Patients with bronchiectasis associated with chronic obstructive pulmonary and
 bronchial asthma.

 8. Patients with severe heart, brain, liver and renal dysfunction.